Albert Kim, MD, PhD
Adjunct Instructor
Boston University School of Medicine
Dept of Medicine
Cardiovascular Medicine

MD, University of California, Los Angeles
PhD, University of California, Los Angeles




Dr. Kim is an accomplished physician-scientist with expertise in cardiovascular disease, translational medicine, and drug development. He earned his undergraduate degree in biomedical engineering from Harvard, MD and PhD degrees from UCLA, completed internal medicine residency at Brigham and Women's Hospital, cardiology fellowship training at MGH, and clinical cardiac electrophysiology training at UCSF. He joined the UCSF faculty and subsequently transitioned to the pharmaceutical industry as a Senior Translational Medicine Expert at Novartis, where he led small molecule and biologic asset programs for hyperlipidemia, inflammation, atherosclerosis, and arrhythmia indications. In 2013 he joined the Pfizer Cardiovascular and Metabolic (CVMET) Research Unit in Cambridge, MA and has served in multiple leadership roles over the past 4 years. He currently serves as VP, Clinical Research Head for CVMET, and oversees clinical research efforts for cardiometabolic diseases such as NASH, diabetes, obesity and heart failure. He has served in advisory and supervisory roles for cardiovascular safety and pharmacovigilance activities, and worked at the FDA in the Division of Cardiac Devices as a medical reviewer and project lead for the industry guidance document on catheter ablation for atrial fibrillation. Beyond his roles at Pfizer, he also holds academic appointments in the VA Boston Cardiac Electrophysiology Section, at Boston University, and at Harvard Medical School.

VA Boston Healthcare System


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Amin NB, Carvajal-Gonzalez S, Purkal J, Zhu T, Crowley C, Perez S, Chidsey K, Kim AM, Goodwin B. Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis. Sci Transl Med. 2019 11 27; 11(520). PMID: 31776293
     
  2. Roth Flach RJ, Su C, Bollinger E, Cortes C, Robertson AW, Opsahl AC, Coskran TM, Maresca KP, Keliher EJ, Yates PD, Kim AM, Kalgutkar AS, Buckbinder L. Myeloperoxidase inhibition in mice alters atherosclerotic lesion composition. PLoS One. 2019; 14(3):e0214150. PMID: 30889221
     
  3. Bass A, Plotka A, Mridha K, Sattler C, Kim AM, Plowchalk DR. Pharmacokinetics, pharmacodynamics, and safety of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, in healthy subjects when administered in co-mixture with recombinant human hyaluronidase: A phase 1 randomized trial. Health Sci Rep. 2018 Sep; 1(9):e61. PMID: 30623096
     
  4. Graham I, Shear C, De Graeff P, Boulton C, Catapano AL, Stough WG, Carlsson SC, De Backer G, Emmerich J, Greenfeder S, Kim AM, Lautsch D, Nguyen T, Nissen SE, Prasad K, Ray KK, Robinson JG, Sasiela WJ, Bruins Slot K, Stroes E, Thuren T, Van der Schueren B, Velkovski-Rouyer M, Wasserman SM, Wiklund O, Zouridakis E. New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. Eur Heart J Cardiovasc Pharmacother. 2018 04 01; 4(2):119-127. PMID: 29194462
     
  5. Kim AM, Somayaji VR, Dong JQ, Rolph TP, Weng Y, Chabot JR, Gropp KE, Talukdar S, Calle RA. Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates. Diabetes Obes Metab. 2017 Dec; 19(12):1762-1772. PMID: 28573777
     
  6. Cowie MR, Filippatos GS, Alonso Garcia MLA, Anker SD, Baczynska A, Bloomfield DM, Borentain M, Bruins Slot K, Cronin M, Doevendans PA, El-Gazayerly A, Gimpelewicz C, Honarpour N, Janmohamed S, Janssen H, Kim AM, Lautsch D, Laws I, Lefkowitz M, Lopez-Sendon J, Lyon AR, Malik FI, McMurray JJV, Metra M, Figueroa Perez S, Pfeffer MA, Pocock SJ, Ponikowski P, Prasad K, Richard-Lordereau I, Roessig L, Rosano GMC, Sherman W, Stough WG, Swedberg K, Tyl B, Zannad F, Boulton C, De Graeff P. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. Eur J Heart Fail. 2017 Jun; 19(6):718-727. PMID: 28345190; DOI: 10.1002/ejhf.809;
     
  7. Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. N Engl J Med. 2017 04 20; 376(16):1517-1526. PMID: 28304227; DOI: 10.1056/NEJMoa1614062;
     
  8. Anker SD, Schroeder S, Atar D, Bax JJ, Ceconi C, Cowie MR, Crisp A, Dominjon F, Ford I, Ghofrani HA, Gropper S, Hindricks G, Hlatky MA, Holcomb R, Honarpour N, Jukema JW, Kim AM, Kunz M, Lefkowitz M, Floch CL, Landmesser U, McDonagh TA, McMurray JJ, Merkely B, Packer M, Prasad K, Revkin J, Rosano GM, Somaratne R, Stough WG, Voors AA, Ruschitzka F. Erratum to "Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency" [Eur J Heart Fail 2016;18:482-489]. Eur J Heart Fail. 2016 06; 18(6):727. PMID: 27324688; DOI: 10.1002/ejhf.591;
     
  9. Anker SD, Schroeder S, Atar D, Bax JJ, Ceconi C, Cowie MR, Crisp A, Dominjon F, Ford I, Ghofrani HA, Gropper S, Hindricks G, Hlatky MA, Holcomb R, Honarpour N, Jukema JW, Kim AM, Kunz M, Lefkowitz M, Le Floch C, Landmesser U, McDonagh TA, McMurray JJ, Merkely B, Packer M, Prasad K, Revkin J, Rosano GM, Somaratne R, Stough WG, Voors AA, Ruschitzka F. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. Eur J Heart Fail. 2016 May; 18(5):482-9. PMID: 27071916; DOI: 10.1002/ejhf.516;
     
  10. Sung RK, Kim AM, Tseng ZH, Han F, Inada K, Tedrow UB, Viswanathan MN, Badhwar N, Varosy PD, Tanel R, Olgin JE, Stephenson WG, Scheinman M. Diagnosis and ablation of multiform fascicular tachycardia. J Cardiovasc Electrophysiol. 2013 Mar; 24(3):297-304. PMID: 23110306; DOI: 10.1111/jce.12020;
     
Showing 10 of 26 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 26 publications over 12 distinct years, with a maximum of 5 publications in 2009

YearPublications
19961
19971
19982
19991
20083
20095
20102
20122
20162
20173
20182
20192

Contact for Mentoring:

72 E. Concord St Building A
Boston MA 02118
Google Map


Kim's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Similar People
_
Same Department